Suchergebnisse

BACKGROUND: Malaria is an important health and economic burden in sub-Saharan Africa. Conventional economic evaluations typically consider only direct costs to the healthcare system and government budgets. This paper quantifies the potential impact of malaria vaccination on the wider economy, using Ghana as an example METHODS: We used a computable general equilibrium model of the Ghanaian economy to estimate the macroeconomic impact of malaria vaccination in children under the age of five, with a vaccine efficacy of 50% against clinical malaria and 20% against malaria mortality. The model considered changes in demography and labor productivity, and projected gross domestic product (GDP) over a time frame of 30 years. Vaccine coverage ranging from 20% to 100% was compared with a baseline with no vaccination. RESULTS: Malaria vaccination with 100% coverage was projected to increase the GDP of Ghana over 30 years by US$6.93 billion (in 2015 prices) above the baseline without vaccination, equivalent to an increase in annual GDP growth of 0.5%. Projected GDP per capita would increase in the first year due to immediate reductions in time lost from work by adults caring for children with malaria, then decrease for several years as reductions in child mortality increase the number of dependent children, then show a sustained increase after Year 11 due to long-term productivity improvements in adults resulting from fewer malaria episodes in childhood. CONCLUSION: Investing in improving childhood health by vaccinating against malaria could result in substantial long-term macroeconomic benefits when these children enter the workforce as adults. These macroeconomic benefits are not captured by conventional economic evaluations and constitute an important potential benefit of vaccination.

The political debate on cannabis policy is often more based on opinions than on evidence. However, evidence-based knowledge is required to design effective cannabis policy. A review of the scientific literature on cannabis policy and its consequences was conducted

This article sets out findings from an independent evaluation of the EU Drugs Strategy 2005–2012 and Action Plans. The research examined the implementation, relevance and influence of the Strategy and its added value for Member States and at EU level.

This article sets out the findings of an evaluation that assesses the degree of implementation of the EU Drugs Strategy 2013–2020 and the Action Plan 2013–2016 in all 28 EU Member States in terms of outputs and, where possible, impacts.